Aprinoia Therapeutics (Aprinoia Therapeutics) Gross-Profit-to-Asset % : 179.61% (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Aprinoia Therapeutics's annualized Gross Profit for the quarter that ended in Jun. 2023 was $18.07 Mil. Aprinoia Therapeutics's average Total Assets over the quarter that ended in Jun. 2023 was $10.06 Mil. Therefore, Aprinoia Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 179.61%.

Aprinoia Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Aprinoia Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Gross-Profit-to-Asset % Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Gross-Profit-to-Asset %

4.31

4.28

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Gross-Profit-to-Asset %	-	4.62	3.51	179.61

Competitive Comparison of Aprinoia Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Aprinoia Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Gross-Profit-to-Asset % falls into.

Aprinoia Therapeutics Gross-Profit-to-Asset % Calculation

Aprinoia Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0.394	/	( (12.766	+	5.643)	/ 2 )
	=	0.394	/	9.2045
	=	4.28 %

Aprinoia Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	18.068	/	( (5.643	+	14.476)	/ 2 )
	=	18.068	/	10.0595
	=	179.61 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Aprinoia Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines